---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Effect on quality measures"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Effect on quality measures. Topics: HEDIS Antidepressant Medication Management (AMM): definition and rationale, HEDIS Antidepressant Medication Management: retirement for measurement year 2025, HEDIS Depression Screening and Follow-Up for Adolescents and Adults (DSF-E): definition, HEDIS Depression Remission or Response for Adolescents and Adults (DRR-E): definition and use of the PHQ-9, and 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/effect-on-quality-measures"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Effect on quality measures

<a id="heading-2.1.2.13"></a>

## 2.1.2.13 Effect of Psilocybin on Quality Measures

<a id="topic-2.1.2.13-1"></a>

### HEDIS Antidepressant Medication Management (AMM): definition and rationale

> “Assesses adults 18 years of age and older with a diagnosis of major depression who were newly treated with antidepressant medication and remained on their antidepressant medications.”
> “Effective Acute Phase Treatment: Adults who remained on an antidepressant medication for at least 84 days (12 weeks).”
> “Effective Continuation Phase Treatment: Adults who remained on an antidepressant medication for at least 180 days (6 months).”
> “Effective medication treatment of major depression can improve a person’s daily functioning and well-being and can reduce the risk of suicide.”

Source: [NCQA Antidepressant Medication Management](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/antidepressant-medication-management-amm/)

<a id="topic-2.1.2.13-2"></a>

### HEDIS Antidepressant Medication Management: retirement for measurement year 2025

> “Retired for Measurement Years 2025 and 2026”
> “This measure only addresses adherence to antidepressants as a treatment for depression and does not address other recommended treatments, such as psychotherapy.”
> “Other HEDIS measures address critical gaps in depression care, including screening, follow-up, routine monitoring and improvement in outcomes.”

Source: [NCQA HEDIS measure retirement plan (2023)](https://www.ncqa.org/blog/retiring-and-replacing-hedis-measures-2024-2026/)

> “For Measurement Year 2025, NCQA added three HEDIS measures, retired four measures and made smaller changes across multiple measures.”
> “The measure does not address other guideline-recommended, non-pharmacological components of care.”
> “NCQA has a more comprehensive set of measures of depression screening, follow-up and routine monitoring, and improvement in outcomes.”

Source: [NCQA HEDIS MY 2025 changes (2024)](https://www.ncqa.org/blog/hedis-my-2025-whats-new-whats-changed-whats-retired/)

<a id="topic-2.1.2.13-3"></a>

### HEDIS Depression Screening and Follow-Up for Adolescents and Adults (DSF-E): definition

> “The percentage of persons 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.”
> “Follow-Up on Positive Screen. The percentage of persons who received follow-up care within 30 days of a positive depression screen finding.”
> “A survey study found that major depressive disorder severity is significantly associated with increased treatment usage and costs, unemployment, disability and reduced work performance”

Source: [NCQA Depression Screening and Follow-Up](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-screening-and-follow-up-for-adolescents-and-adults-dsf-e/)

<a id="topic-2.1.2.13-4"></a>

### HEDIS Depression Remission or Response for Adolescents and Adults (DRR-E): definition and use of the PHQ-9

> “The percentage of persons 12 years of age and older with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 120−240 days (4–8 months) of the elevated score.”
> “Depression Remission. The percentage of persons who achieved remission within 120−240 days (4–8 months) after the initial elevated PHQ-9 score.”
> “Depression Response. The percentage of persons who showed response within 120−240 days (4–8 months) after the initial elevated PHQ-9 score.”
> “The PHQ-9 is widely used by clinicians in the U.S. and commonly accepted in the behavioral health field as well.”

Source: [NCQA Depression Remission or Response](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/depression-remission-or-response-for-adolescents-and-adults-drr-e/)

<a id="topic-2.1.2.13-5"></a>

### Electronic clinical quality measure CMS159v14, Depression Remission at Twelve Months: definition and rationale

> “MIPS Quality ID 370”
> “The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event”
> “Adolescent patients 12 to 17 years of age and adult patients 18 years of age and older who achieved remission at twelve months as demonstrated by the most recent twelve month (+/- 60 days) PHQ-9 or PHQ-9M score of less than five”
> “Results from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study showed that remission rates lowered with more treatment steps, but the overall cumulative rate was 67% (Rush et al., 2006).”

Source: [eCQI Resource Center CMS159 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0159v14)

<a id="topic-2.1.2.13-6"></a>

### Electronic clinical quality measure CMS2v15, Screening for Depression and Follow-Up Plan: definition

> “MIPS Quality ID 134”
> “Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of or up to two days after the date of the qualifying encounter”
> “Updated numerator to include patients who have an active depression medication overlapping the date of the qualifying encounter.”

Source: [eCQI Resource Center CMS2 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0002v15)

<a id="topic-2.1.2.13-7"></a>

### Medicaid Adult Core Set: mandatory depression screening measure for 2027

> “2027 Mandatory Adult Core Set Measures”
> “672 CMS Screening for Depression and Follow-Up Plan: Age 18 and Older (CDF-AD) Administrative or EHR”

Source: [CMS 2027 Adult Core Set](https://www.medicaid.gov/medicaid/quality-of-care/downloads/2027-adult-core-set.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
